The peptide and protein field is well established. Nevertheless, innovations in this area are constantly emerging.
Our team has significant experience across this field, including small peptide therapeutics, peptide vaccines, cytokine fusions and recombinant fusion proteins, whether used as therapeutics or in diagnosis.
It is because of this experience that our attorneys understand the challenges faced by innovators in this field, especially in view of the more recent shift towards a more personalised approach to treating a patient. Whether the invention lies in the identification of fusion proteins and their use in characterising patients, or tailoring treatments for particular patients using recombinant fusion proteins or perhaps even designing personalised peptide vaccines, our attorneys have significant expertise in advising clients how to maximise protection in this area and adapt their IP strategy accordingly.
